Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 10Gastrointestinal 1

Conditions

Stomach Neoplasms 19Carcinoma, Hepatocellular 18Pancreatic Neoplasms 14Colorectal Neoplasms 12Esophageal Neoplasms 9Neoplasm Metastasis 8Esophageal Squamous Cell Carcinoma 7Biliary Tract Neoplasms 7Lung Neoplasms 6Liver Neoplasms 6Cholangiocarcinoma 6Breast Neoplasms 6Neoplasms 5Colonic Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Melanoma 3Sarcoma 2Rectal Neoplasms 2Advanced Pancreatic Cancer 2Uveal Melanoma 1Uterine Cervical Neoplasms 1Tuberous Sclerosis 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Resectable Esophageal Squamous Cell Carcinoma 1Recurrence 1Prostatic Neoplasms 1Pancreatic Cancer Metastatic 1Ovarian Neoplasms 1Oligometastatic Gastrointestinal Cancer 1

Interventions

pembrolizumab 39Nivolumab 15Gemcitabine 8spartalizumab 7atezolizumab 7Carboplatin 7Cyclophosphamide 6130-nm albumin-bound paclitaxel 6durvalumab 5Cisplatin 5Bevacizumab 5fludarabine 4budigalimab 4Paclitaxel 4Oxaliplatin 4Leucovorin 4Ipilimumab 4Fluorouracil 4Cetuximab 4Albumin-Bound Paclitaxel 4tislelizumab 3lenvatinib 3cemiplimab 3avelumab 3Specimen Handling 3Magnetic Resonance Spectroscopy 3Irinotecan 3HMPL-013 3Fulvestrant 3Docetaxel 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Injections × Gastrointestinal × Clear all
NCT06078670 2023-10-12

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Fujian Cancer Hospital

Phase 1/2 Not yet recruiting
96 enrolled
BreastGastrointestinal

Intestinal Neoplasms, Stomach Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡